1. Market Research
  2. > Pharmaceutical
  3. > Drug Discovery and Development Market Trends
  4. > Malignant Mesothelioma Global Clinical Trials Review, H2, 2015

Malignant Mesothelioma Global Clinical Trials Review, H2, 2015

Summary

GlobalData's clinical trial report, “Malignant Mesothelioma Global Clinical Trials Review, H2, 2015" provides an overview of Malignant Mesothelioma clinical trials scenario. This report provides top line data relating to the clinical trials on Malignant Mesothelioma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Data’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Malignant Mesothelioma Global Clinical Trials Review, H2, 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Malignant Mesothelioma 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Malignant Mesothelioma to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Malignant Mesothelioma to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Malignant Mesothelioma 25
Subjects Recruited Over a Period of Time 29
Clinical Trials by Sponsor Type 30
Prominent Sponsors 31
Top Companies Participating in Malignant Mesothelioma Therapeutics Clinical Trials 32
Prominent Drugs 33
Latest Clinical Trials News on Malignant Mesothelioma 34
Jun 15, 2015: EnGeneIC and Asbestos Diseases Research Institute Announce Encouraging Results from MesomiR-1 Phase 1 Trial in Late Stage Mesothelioma patients 34
Jun 01, 2015: Oral presentation at ASCO 2015 of survival data in poor prognosis patients achieved in the Phase III trial on NGR-hTNF treatment in pleural mesothelioma 34
May 30, 2015: Collaborative group phase III study shows Roche's Avastin improves survival in patients with mesothelioma - a devastating type of thoracic cancer 35
May 29, 2015: ArQule Announces Data Presentations with Tivantinib to Be Featured at ASCO 2015 36
May 27, 2015: Genelux Announces Promising Data From Two Phase I Trials of GL-ONC1 in Head and Neck Cancer and Mesothelioma 36
May 07, 2015: Concordia Healthcare Works To Expand Treatment Options For Patients With Rare Cancers 38
Apr 17, 2015: Bionomics Showcases BNC105 Oncology Drug Development Program At 2015 AACR Annual Meeting 39
Clinical Trial Profiles 40
Clinical Trial Overview of Top Companies 40
Eli Lilly and Company 40
Clinical Trial Overview of Eli Lilly and Company 40
Novartis AG 42
Clinical Trial Overview of Novartis AG 42
AstraZeneca Plc 43
Clinical Trial Overview of AstraZeneca Plc 43
Verastem, Inc. 44
Clinical Trial Overview of Verastem, Inc. 44
Pfizer Inc. 45
Clinical Trial Overview of Pfizer Inc. 45
Merck Sharp and Dohme Corp. (Inactive) 46
Clinical Trial Overview of Merck Sharp and Dohme Corp. (Inactive) 46
Merck and Co., Inc. 47
Clinical Trial Overview of Merck and Co., Inc. 47
F. Hoffmann-La Roche Ltd. 48
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 48
Eisai Inc. 49
Clinical Trial Overview of Eisai Inc. 49
Aduro BioTech, Inc. 50
Clinical Trial Overview of Aduro BioTech, Inc. 50
Clinical Trial Overview of Top Institutes / Government 51
National Cancer Institute 51
Clinical Trial Overview of National Cancer Institute 51
European Organization for Research and Treatment of Cancer 56
Clinical Trial Overview of European Organization for Research and Treatment of Cancer 56
Dana-Farber Cancer Institute, Inc. 57
Clinical Trial Overview of Dana-Farber Cancer Institute, Inc. 57
Memorial Sloan Kettering Cancer Center 58
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 58
Hyogo College Of Medicine 59
Clinical Trial Overview of Hyogo College Of Medicine 59
Istituto Clinico Humanitas 60
Clinical Trial Overview of Istituto Clinico Humanitas 60
Sir Charles Gairdner Hospital 61
Clinical Trial Overview of Sir Charles Gairdner Hospital 61
The Cancer and Leukemia Group B 62
Clinical Trial Overview of The Cancer and Leukemia Group B 62
Abramson Cancer Center 63
Clinical Trial Overview of Abramson Cancer Center 63
Columbia University 64
Clinical Trial Overview of Columbia University 64
Five Key Clinical Profiles 65
Appendix 95
Abbreviations 95
Definitions 95
Research Methodology 96
Secondary Research 96
About GlobalData 97
Contact Us 97
Disclaimer 97
Source 98

List of Tables

Malignant Mesothelioma Therapeutics, Global, Clinical Trials by Region, 2015* 7
Malignant Mesothelioma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Malignant Mesothelioma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Malignant Mesothelioma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015* 10
Malignant Mesothelioma Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11
Malignant Mesothelioma Therapeutics Clinical Trials, North America, Top Countries, 2015* 12
Malignant Mesothelioma Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* 13
Malignant Mesothelioma Therapeutics Clinical Trials, Central and South America, Top Countries, 2015* 14
Proportion of Malignant Mesothelioma to Oncology Clinical Trials, G7 Countries (%), 2015* 15
Malignant Mesothelioma Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16
Malignant Mesothelioma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17
Proportion of Malignant Mesothelioma to Oncology Clinical Trials, E7 Countries (%), 2015* 18
Malignant Mesothelioma Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19
Malignant Mesothelioma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 20
Malignant Mesothelioma Therapeutics, Global, Clinical Trials by Phase, 2015* 21
Malignant Mesothelioma Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 22
Malignant Mesothelioma Therapeutics, Global, Clinical Trials by Trial Status, 2015* 23
Malignant Mesothelioma Therapeutics Clinical Trials, Global, by End Point Status, 2015* 24
Malignant Mesothelioma Therapeutics, Global, Suspended Clinical Trials, 2015* 25
Malignant Mesothelioma Therapeutics, Global, Withdrawn Clinical Trials, 2015* 26
Malignant Mesothelioma Therapeutics, Global, Terminated Clinical Trials, 2015* 27
Malignant Mesothelioma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 29
Malignant Mesothelioma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 30
Malignant Mesothelioma Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 31
Malignant Mesothelioma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 32
Malignant Mesothelioma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 33
Malignant Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2015* 40
Malignant Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2015* 42
Malignant Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca Plc, 2015* 43
Malignant Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Verastem, Inc., 2015* 44
Malignant Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2015* 45
Malignant Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck Sharp and Dohme Corp. (Inactive), 2015* 46
Malignant Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck and Co., Inc., 2015* 47
Malignant Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2015* 48
Malignant Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Eisai Inc., 2015* 49
Malignant Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Aduro BioTech, Inc., 2015* 50
Malignant Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2015* 51
Malignant Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by European Organization for Research and Treatment of Cancer, 2015* 56
Malignant Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Dana-Farber Cancer Institute, Inc., 2015* 57
Malignant Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2015* 58
Malignant Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Hyogo College Of Medicine, 2015* 59
Malignant Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Istituto Clinico Humanitas, 2015* 60
Malignant Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Sir Charles Gairdner Hospital, 2015* 61
Malignant Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by The Cancer and Leukemia Group B, 2015* 62
Malignant Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Abramson Cancer Center, 2015* 63
Malignant Mesothelioma Therapeutics Clinical Trials Market, Global, Clinical Trials by Columbia University, 2015* 64

List of Figures
Malignant Mesothelioma Therapeutics, Global, Clinical Trials by Region (%), 2015* 7
Malignant Mesothelioma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Malignant Mesothelioma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Malignant Mesothelioma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015* 10
Malignant Mesothelioma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11
Malignant Mesothelioma Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 12
Malignant Mesothelioma Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2015* 13
Malignant Mesothelioma Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2015* 14
Proportion of Malignant Mesothelioma to Oncology Clinical Trials, G7 Countries (%), 2015* 15
Malignant Mesothelioma Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16
Malignant Mesothelioma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17
Proportion of Malignant Mesothelioma to Oncology Clinical Trials, E7 Countries (%), 2015* 18
Malignant Mesothelioma Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19
Malignant Mesothelioma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 20
Malignant Mesothelioma Therapeutics, Global, Clinical Trials by Phase (%), 2015* 21
Malignant Mesothelioma Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 22
Malignant Mesothelioma Therapeutics, Global, Clinical Trials by Trial Status, 2015* 23
Malignant Mesothelioma Therapeutics Clinical Trials, Global, by End Point Status, 2015* 24
Malignant Mesothelioma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 29
Malignant Mesothelioma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 30
Malignant Mesothelioma Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 31
Malignant Mesothelioma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 32
Malignant Mesothelioma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 33
GlobalData Methodology 96

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

  • $ 5650
  • Industry report
  • August 2016
  • by MarketsandMarkets

The global clinical trial management system (CTMS) market is estimated to grow at a CAGR of 11.5% from 2016 to 2021, to reach USD 920.0 billion by 2021. The adoption of CTMS software is on the rise across ...

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global CRO services market is estimated to grow at a CAGR of 7.4% from 2016 to 2021, to reach USD 41.86 billion by 2021 from USD 29.29 billion in 2016. Growth in this market is primarily attributed ...

Clinical Trial Management System (CTMS) - Global Market Outlook (2016-2022)

Clinical Trial Management System (CTMS) - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • November 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Clinical Trial Management System (CTMS) market is expected to grow from $493.58 million in 2015 to reach $1118.58 million by 2022 with a CAGR of 12.4%. Huge research ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.